Evidence map›Paper›PMID 28579059›Full record

ReviewNeurochemistry international2018

Neuroketotherapeutics: A modern review of a century-old therapy.

Scott J Koppel, Russell H Swerdlow

Abstract readReview
In one paragraph

Review in Neurochemistry international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 2 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 142 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Energy metabolism in health and diseases.Signal transduction and targeted therapy · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Scott J KoppelUniversity of Kansas Alzheimer's Disease Center, KS, USA; Department of Molecular and Integrative Physiology, University of Kansas Medical Center, KS, USA.
Russell H SwerdlowUniversity of Kansas Alzheimer's Disease Center, KS, USA; Department of Molecular and Integrative Physiology, University of Kansas Medical Center, KS, USA; Department of Neurology, University of Kansas Medical Center, KS, USA; Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, KS, USA. Electronic address: rswerdlow@kumc.edu.
University of Kansas · US

Funding

University of Kansas Alzheimer's Disease Research Center (KU ADRC)P30AG072973 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Jaime Perales Puchalt · 2021 to 2026
$25.3M
University of Kansas Alzheimer's Disease Core CentersP30AG035982 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BROOKS, WILLIAM M. · 2011 to 2020
$16.6M
Kansas University Training Program in Neurological and Rehabilitation SciencesT32HD057850 · NICHD · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Jacob J. Sosnoff · 2009 to 2026
$3.4M
NIA NIH HHS P30 AG035982NIA NIH HHS P30 AG072973NICHD NIH HHS T32 HD057850
6 · The paper itself

Abstract

Neuroketotherapeutics represent a class of bioenergetic medicine therapies that feature the induction of ketosis. These therapies include medium-chain triglyceride supplements, ketone esters, fasting, strenuous exercise, the modified Atkins diet, and the classic ketogenic diet. Extended experience reveals persons with epilepsy, especially pediatric epilepsy, benefit from ketogenic diets although the mechanisms that underlie its effects remain unclear. Data indicate ketotherapeutics enhance mitochondrial respiration, promote neuronal long-term potentiation, increase BDNF expression, increase GPR signaling, attenuate oxidative stress, reduce inflammation, and alter protein post-translational modifications via lysine acetylation and β-hydroxybutyrylation. These properties have further downstream implications involving Akt, PLCγ, CREB, Sirtuin, and mTORC pathways. Further studies of neuroketotherapeutics will enhance our understanding of ketone body molecular biology, and reveal novel central nervous system therapeutic applications.

Indexed as

Alzheimer DiseaseAnimalsDiet, KetogenicEnergy MetabolismEpilepsyHumansKetone BodiesKetosisMitochondriaOxidative StressKetone BodiesAlzheimer's diseaseBioenergeticsKetogenic dietKetone bodiesMitochondriaβ-hydroxybutyrate

Identifiers

PMID28579059
PMCPMC5711637
OpenAlexW2621303490

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.